This is a working overview of Alpha-MSH, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-05. Anything still debated is marked as such rather than presented as settled.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Thereafter, the amount of carbon-14 in organic matter decreases according to decay processes that may also be independently cross-checked by other means (such as checking the carbon-14 in individual tree rings, for example).
The reaction is carried out at elevated temperature, and beside sodium hydroxide or potassium hydroxide, calcium hydroxide, barium hydroxide, magnesium hydroxide, or carbonates of alkali or alkaline earth metals can be used. With a high yield (90%) ethylene oxide can be produced by treating calcium oxide with ethyl hypochlorite; substituting calcium by other alkaline earth metals reduces the reaction yield:
Ian Goldin professor at University of Oxford, author of over twenty books and 60 scholarly academic monographs, founding director of the Oxford Martin School at the University of Oxford; currently the director of the Oxford Martin Research Programmes on Technological and Economic Change, Future of Work and Future of Development; also Professor of Globalisation and Development and holds a professorial fellowship at Balliol College at the University of Oxford; was principal economist at the European Bank for Reconstruction and Development (EBRD) in London, and program director at the OECD in Paris, where he directed the Development Centre's Programs on Trade, Environment and Sustainable Development; was chief executive and managing director of the Development Bank of Southern Africa (DBSA); served as adviser to President Nelson Mandela; Louis Golding novelist Lawrence Goldman (b.1957) ; historian, academic, Executive Editor of History Reclaimed, journalist; has written for Daily Mail, The Guardian, The Daily Telegraph, was director of the Oxford Dictionary of National Biography and of the Institute of Historical Research, University of London. Vivien Goldman British author and academic of German Jewish ancestry, focusing on the historiography, Praxis (process), dialectic and epistemology of punk rock, dub, and reggae.
Alpha-fetoprotein (AFP) is significantly expressed in foetal liver. However, the mechanism that led to the suppression of AFP synthesis in adults is not fully known. Exposure of the liver to cancer-causing agents and arrest of liver maturation in childhood can lead to the rise in AFP. AFP can reach until 400–500 μg/L in hepatocellular carcinoma. AFP concentration of more than 400 μg/L is associated with greater tumour size, involvement of both lobes of liver, portal vein invasion and a lower median survival rate.
Thiol additives : The initial transthioesterification step of the native chemical ligation reaction is catalyzed by thiol additives. The most effective and commonly used thiol catalyst is 4-mercaptophenylacetic acid (MPAA), (ref).
Sources: en.wikipedia.org
However, atheromas within the vessel wall are soft and fragile with little elasticity. Arteries constantly expand and contract with each heartbeat, i.e., the pulse. In addition, calcification deposits between the outer portion of the atheroma and the muscular wall, as they progress, lead to a loss of elasticity and stiffening of the artery as a whole. The calcification deposits, after they have become sufficiently advanced, are partially visible on coronary artery computed tomography or electron beam tomography (EBT) as rings of increased radiographic density, forming halos around the outer edges of the atheromatous plaques, within the artery wall. On CT, >130 units on the Hounsfield scale (some argue for 90 units) has been the radiographic density usually accepted as clearly representing tissue calcification within arteries. These deposits demonstrate unequivocal evidence of the disease, relatively advanced, even though the lumen of the artery is often still normal by angiography.
=== During the United Monarchy === As a monarchic state, the Israelite tribes were united by the leadership of Saul, David and Solomon. The reigns of Saul and David were marked by military victories and Israel's transition to a mini-empire with vassal states. Solomon's reign was relatively more peaceful and oversaw the construction of the First Temple, with the help of Phoenician allies. This Temple was where the Ark of the Covenant was stored; its former location was the City of David. This period is covered by 1 Samuel 8 to 1 Kings 11 or alternatively, 1 Chronicles 10 to 2 Chronicles 9.
For example, the Archbishop of Reggio Calabria, Carmelo Pujia, an interventionist on the eve of World War, had a prayer composed praising the glory of the homeland and the Italian flag. Under the Fascist regime, concentration camps were built in Calabria and used to imprison foreigners whose presence was considered undesirable, such as Chinese immigrants and foreign (though not Italian) Jews together with members of the Romani minority, whose nomadic lifestyle was viewed as anti-social. The camps operated from 1938 to 1943. They were harsh, butt not death camps, (the majority of those imprisoned survived).
== Medical uses == Liraglutide is an anti-diabetic medication used for the treatment of type 2 diabetes or obesity. Liraglutide (Victoza) is indicated as an adjunct to diet and exercise to improve glycemic control in people aged ten years of age and older with type 2 diabetes; and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Liraglutide (Saxenda) is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in people aged twelve years of age and older with body weight greater than 60 kilograms (130 lb) and obesity; and in adults with overweight in the presence of at least one weight-related comorbid condition.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.